MARKET

CLNNW

CLNNW

Clene
NASDAQ
0.1067
+0.0067
+6.70%
Closed 16:00 01/27 EST
OPEN
0.1000
PREV CLOSE
0.1000
HIGH
0.1071
LOW
0.1000
VOLUME
2.53K
TURNOVER
258
52 WEEK HIGH
0.6000
52 WEEK LOW
0.0247
MARKET CAP
--
P/E (TTM)
-0.2766
1D
5D
1M
3M
1Y
5Y
BRIEF-Clene Reports Topline Results Of Phase 2 Covid-19 Study Of CNM-ZnAg
Reuters · 12/27/2022 21:55
BRIEF-Clene Enters Into Amendment No. 1 To Equity Distribution Agreement
Reuters · 12/20/2022 11:23
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapi...
GlobeNewswire · 11/28/2022 13:00
BRIEF-Clene Reports Third Quarter 2022 Financial Results And Recent Operating Highlights
Reuters · 11/07/2022 13:59
BRIEF-Clene Announces $10.8 Million Registered Direct Offering And $5 Million Debt Facility From The State Of Maryland
Reuters · 10/31/2022 12:14
BRIEF-Clene Reports Topline Results Demonstrating Survival Signal For CNM-AU8® In Healey Als Platform Trial
BRIEF-Clene Reports Topline Results Demonstrating Survival Signal For CNM-AU8® In Healey Als Platform Trial
Reuters · 10/03/2022 12:36
BRIEF-Clene Nanomedicine Presents Updated Long-Term Survival Data From Rescue-ALS Participants
BRIEF-Clene Nanomedicine Presents Updated Long-Term Survival Data From Rescue-ALS Participants
Reuters · 09/21/2022 11:33
Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of...
GlobeNewswire · 08/30/2022 11:00
More
About CLNNW
Clene Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The Company has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

Webull offers kinds of Clene Inc. stock information, including NASDAQ:CLNNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLNNW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLNNW stock methods without spending real money on the virtual paper trading platform.